Arcutis Announces Appointment of Sue-Jean Lin to Board of Directors
09 Juin 2021 - 10:01PM
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage
biopharmaceutical company focused on developing and commercializing
treatments for unmet needs in immune-mediated dermatological
diseases and conditions, or immuno-dermatology, today announced
that Sue-Jean Lin has been appointed to the Arcutis Board of
Directors effective June 9, 2021, and that Jonathan Silverstein,
J.D. has decided to step down from the Board for personal reasons.
“We thank Jonathan for his outstanding contributions to
Arcutis,” commented Patrick Heron, Chairman of the Arcutis Board of
Directors. “His leadership was instrumental in driving the
continued success of the company over the past 4 years, including
providing invaluable input to multiple successful private and
public financings. We wish him all the best in his future
endeavors, and we will deeply miss his intellect, humor and
friendship.”
“We are pleased to welcome Sue-Jean to the Arcutis Board,” said
Frank Watanabe, Arcutis’ President and Chief Executive Officer.
“She brings unique and very deep digital and information technology
expertise to our board, as well as extensive executive experience
in the life sciences industry. With 30 years of digital,
operational, financial, and leadership experience in driving higher
business performance for global pharmaceutical companies, Sue-Jean
will play a critical role in guiding Arcutis as we expand and
advance our pipeline of novel immuno-dermatology drug candidates
and prepare for our first potential commercial launch.”
“I am thrilled to join the Arcutis board at this pivotal time,”
said Sue-Jean Lin. “The Company’s lead product candidate, topical
roflumilast, shows strong promise as an innovative treatment for
skin diseases where there is currently significant unmet need. I
look forward to supporting the company’s growth trajectory with my
insight and expertise, specifically in digital transformation,
information technology, finance, risk management, and commercial
operations.”
Ms. Lin is Senior Vice President and Chief Information Officer
at Alcon (NYSE: ALC), a global leader in eye care where she played
a key role during its journey to becoming an independent, publicly
traded company. Prior to Alcon, she was a member of the Hill-Rom
executive leadership team, serving in the capacity of Senior Vice
President and Chief Information Officer. Here she was instrumental
in developing a new business model that enabled patient engagement
and improved the effectiveness of biomedical professionals. During
her career she also served multiple roles at Allergan, including as
the Senior Vice President and Chief Information Officer, and as the
regional Chief Financial Officer for Allergan’s Europe, Middle
East, Africa, and Asia Pacific commercial operations. Ms. Lin holds
a bachelor’s degree in accounting and a master’s degree in business
administration from the University of Nevada, Reno.About
ArcutisArcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a
late-stage biopharmaceutical company focused on developing and
commercializing treatments for unmet needs in immune-mediated
dermatological diseases and conditions, or immuno-dermatology. The
company is leveraging recent advances in immunology and
inflammation to develop differentiated therapies against
biologically validated targets to solve persistent treatment
challenges in serious diseases of the skin. Arcutis’
robust pipeline includes four novel drug candidates
currently in development for a range of inflammatory dermatological
conditions. The company’s lead product candidate, topical
roflumilast, has the potential to revitalize the standard of care
for plaque psoriasis, atopic dermatitis, scalp psoriasis, and
seborrheic dermatitis. For more information,
visit www.arcutis.com or follow the company
on LinkedIn and Twitter.
Forward-Looking StatementsThis press release
contains "forward-looking" statements, including, among others,
statements regarding the potential for roflumilast to revolutionize
the standard of care in plaque psoriasis and other inflammatory
dermatological conditions. These statements involve substantial
known and unknown risks, uncertainties and other factors that may
cause our actual results, levels of activity, performance, or
achievements to be materially different from the information
expressed or implied by these forward-looking statements and you
should not place undue reliance on our forward-looking statements.
Risks and uncertainties that may cause our actual results to differ
include risks inherent in the clinical development process and
regulatory approval process, the timing of regulatory filings, and
our ability to defend our intellectual property. For a further
description of the risks and uncertainties applicable to our
business, see the "Risk Factors" section of our Form 10-K filed
with U.S. Securities and Exchange Commission (SEC) on February 16,
2021, as well as any subsequent filings with the SEC. We undertake
no obligation to revise or update information herein to reflect
events or circumstances in the future, even if new information
becomes available.
Investor and Media Contact:ir@arcutis.com
Alcon (NYSE:ALC)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Alcon (NYSE:ALC)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024